Cutaneous T-cell lymphoma (CTCL)
- Skin-limited disease starts with skin-directed therapy
- Topical steroid/retinoid/phototherapy are common
- Advanced disease uses systemic targeted agents
- Brentuximab for CD30-positive selected disease
- Mogamulizumab/HDAC inhibitors are other options
- Avoid overtreatment of indolent early disease
Use at a glance
- Skin-limited disease starts with skin-directed therapy
Treatment options
- Topical steroid/retinoid/phototherapy are common
- Mogamulizumab/HDAC inhibitors are other options
Choosing treatment
- Advanced disease uses systemic targeted agents
- Brentuximab for CD30-positive selected disease
Safety / pitfalls
- Avoid overtreatment of indolent early disease
Self-check
- What should generally be avoided in Cutaneous T-cell lymphoma (CTCL)?
overtreatment of indolent early disease.
Drugs used for this (3)
All clinical uses · Open the interactive console ↗
